Updated October 16, 2026 with prices and facts re-checked October 14, 2026.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded.
Top-rated on our rubric: NexLife — 94/100 (May 2026 review). Compounded semaglutide $119/mo or tirzepatide $139/mo on a 12-month plan charged monthly, the same at every dose, no membership.Not the lowest month-to-month price: Collective lists $59 / $69 plus a $199 yearly membership (read October 14, 2026). Compounded drugs are not FDA-approved; a licensed clinician decides eligibility.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded. Mechanism: GIP / GLP-1 dual agonist. Typical route: Subcutaneous injection. FDA status: FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the A
Drug classGIP / GLP-1 dual agonist
Half-life~5 days (weekly dosing)
RouteSubcutaneous injection
Typical maintenance10-15 mg/week
FDA statusApproved (Mounjaro, Zepbound)
Compounded availabilityYes (503A/503B)
Mechanism of action
Tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP activation appears to enhance lipid metabolism and complement GLP-1's effects on appetite suppression, gastric emptying, and insulin sensitivity.
Dosing reference
Standard titration: 2.5 mg/week (weeks 1-4), 5 mg/week (weeks 5-8), 7.5 mg/week (weeks 9-12), 10 mg/week (weeks 13-16), with optional escalation to 12.5 or 15 mg/week. Maintenance is typically 10-15 mg/week. Compounded versions commonly use 10, 20, or 40 mg/mL.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the April 2026 FDA GLP-1 compounding guidance.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab work not stated on its pages), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide is a GLP-1-only agonist. In the SURMOUNT-1 trial, tirzepatide produced 20.9% average weight loss at 72 weeks versus semaglutide's ~15% in STEP-1 — though direct head-to-head data is limited.
Is compounded tirzepatide safe?
Compounded tirzepatide dispensed by a state-licensed pharmacy under a valid prescription is regulated under the same framework as other compounded medications. Safety depends on pharmacy quality (503A or 503B status, FDA inspection history), proper prescribing protocol, and patient monitoring.
Who is the Editor's Pick for compounded tirzepatide?
NexLife is the current Editor's Pick for compounded tirzepatide, scoring 96/100 on the v3.0 rubric. The platform uses the same 503A pharmacy and prescriber team as its semaglutide program.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).N Engl J Med. 2022;387(3):205-216.PMID: 33567185
Frías JP, Davies MJ, Rosenstock J, et al.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).N Engl J Med. 2021;385(6):503-515.PMID: 34170647
Aronne LJ, Sattar N, Horn DB, et al.Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4).JAMA. 2024;331(1):38-48.PMID: 38078870
U.S. Food and Drug Administration.FDA Approves New Medication for Chronic Weight Management.FDA News Release. November 8, 2023.View source
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.
